Research Article

Analysis of Various Types of Glomerulonephritis with Crescents at a Single Center

Tomo Nakakita, Kenichi Akiyama, Kazunori Karasawa, Yoei Miyabe, Takahito Moriyama, Keiko Uchida, and Kosaku Nitta

Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan

Correspondence should be addressed to Kazunori Karasawa; ichitoku@hotmail.co.jp

Received 6 September 2021; Revised 11 April 2022; Accepted 12 April 2022; Published 9 May 2022

1. Introduction

Histopathologically, crescentic glomerulonephritis (CreGN) with cellular, fibrocellular, and fibrous crescent formation is typically observed in patients with rapidly progressive glomerulonephritis (RPGN) [1]. CreGN is defined as nephritis in which more than 50% of the glomeruli sampled in a renal biopsy show crescents [2]. Until recently, many reports have classified CreGN and/or RPGN into the following three types based on immunofluorescence microscopy findings: type I or antiglomerular basement membrane (GBM) disease was defined as a linear deposition of immunoglobulins along the GBM and is the typical presentation; type II, which included immunoglobulin A nephropathy (IgA-N) and lupus nephritis (LN), was defined as glomerular immune-complex deposition; and type III, or antineutrophil cytoplasmic autoantibody (ANCA)-related nephritis, which includes microscopic polyangiitis (MPA), was defined as a pauci-immune deposition [3, 4].

Recent improvements in diagnostic techniques, such as in the measurement method of serum ANCA titers, have enabled diagnosis before the exact pathological definition of CreGN is fulfilled [1]. Thus, in many cases, a diagnosis is made before renal biopsy results are obtained, even though
the criteria do not meet the strict definition. This has led to an increasing number of RPGN cases over the past decade; however, it has been speculated that the number of CreGN cases fulfilling the strict criteria may not have increased [5]. Therefore, the number of cases with glomerulonephritis and crescent formation is expected to have increased, yet few reports have analyzed only cases of glomerulonephritis in which crescents were formed. Therefore, there is insufficient evidence to support that the present definition of CreGN accurately reflects the actual clinical situation.

The detailed molecular mechanism involved in crescent formation has not yet been elucidated. However, pathological findings commonly show glomerular loop ruptures, regardless of the underlying disease [6]. The presence and ratio of crescent formation in various glomerulonephritis types have recently been evaluated, and the ratio of crescent formation was added to the Oxford pathological classification of IgA-N [7]. The International Society of Nephrology and the Society of Renal Pathology classification defines crescents as active lesions in cases of LN [8]. Accordingly, we hypothesized that the presence of even one crescentic lesion could be an important factor in predicting renal prognosis and determining treatment for any type of underlying glomerulonephritis. Therefore, we conducted the present retrospective study of glomerulonephritis cases in which at least one crescent was detected using renal biopsy.

2. Materials and Methods

2.1. Patients. We examined cases at our hospital using the classification described in a previous report that classified and reported three types of CreGN [3, 4]. None of the cases of anti-GBM disease corresponded to the criteria for type I glomerulonephritis with crescents in our hospital among the three classifications. Patients who were serologically positive for anti-GBM antibodies but did not undergo renal biopsy were excluded. Type II glomerulonephritis with crescents was heterogeneous. According to this definition, IgA-N was the type observed most often, followed by LN and IgA vasculitis with nephritis (IgA-VN), accounting for 95% of cases with these three diseases. Other cases with type III glomerulonephritis with crescents were excluded because there were very few cases. In this study, we further analyzed type II glomerulonephritis with crescents by dividing it into three diseases (IgA-N, LN, and IgA-VN). Type III glomerulonephritis with crescents has regional characteristics. In Japan, it is predominantly MPA, and almost no other cases of vasculitis can be regarded as a single disease. Therefore, glomerulonephritis with crescents in our hospital was reclassified into four groups based on the presence of IgA-N, IgA-VN, LN, MPA, and the underlying disease.

Renal biopsy-proven MPA, IgA-N, IgA-VN, and LN with the observation of at least one crescent on histopathology results between January 2000 and April 2018 at the Tokyo Women’s Medical University Hospital were included in this study. The findings of crescent formation included cellular, fibrocellular, and fibrous crescents. Renal biopsy was performed between April 2003 and April 2007. The exclusion criteria included patients aged under 16 years at the time of renal biopsy, patients with a follow-up period of less than one year, and patients with IgA-N who underwent tonsillectomy. The endpoints were dialysis induction, death, and one-year survival rate. A total of 196 cases were extracted, including 47 (24.0%) cases of MPA, 78 (39.8%) cases of IgA-N, 31 (15.8%) cases of IgA-VN, and 40 (20.4%) cases of LN. This study complied with the guidelines of the Declaration of Helsinki and was approved by our institutional ethics committee (#4811). We received verbal consent from all patients, and we provided them with the opportunity to opt out. This method of obtaining consent was approved by the ethics committee of Tokyo Women’s Medical University.

2.2. Clinical Findings. Clinical data included sex, age, body mass index (BMI), systolic, diastolic, and mean arterial pressure (MAP), interval between renal biopsy onset (interval from onset), and laboratory data such as serum total protein, serum albumin (Alb), blood urea nitrogen, and serum creatinine levels; estimated glomerular filtration rate (eGFR); serum uric acid levels; total cholesterol, low-density lipoprotein-cholesterol, and triglyceride levels; IgG; IgA; IgM; C3; C4; CH50; urinary protein excretion; urinary red blood cell count (U-RBC); and complications (e.g., hypertension, dyslipidemia, and hyperuricemia). U-RBC was assessed using semi-quantitative analysis as a null count of RBC/high-power field (HPF) as follows: <1 RBC/20 HPF, 1 RBC/10–19 HPF, 1 RBC/5–9 HPF, 1 RBC/1–5 HPF, 1–5 RBCs/HPF, 5–9 RBCs/HPF, 10–19 RBCs/HPF, 20–29 RBCs/HPF, 30–49 RBCs/HPF, 50–99 RBCs/HPF, and ≥100 RBCs/HPF, and we selected the lowest number of RBCs in each grade as the U-RBC value. We also determined whether angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or antiplatelet drugs were administered.

2.3. Histological Findings. Light microscopy (LM) findings were reviewed by expert renal pathologists at the time of the original report. The recorded LM findings included the following: global glomerulosclerosis percentage, crescent type (cellular/fibrocellular/fibrous), relative to the total number of glomeruli, and tubular atrophy and interstitial fibrosis based on the tubulointerstitial compartment. These findings were graded as follows: the extent of global glomerulosclerosis was graded into five categories: grade 0, lesion < 10%; grade 1, 10% ≤ lesion < 25%; grade 2, 25% ≤ lesion < 50%; grade 3, 50% ≤ lesion < 75%; and grade 4, lesion ≥ 75%. The extent of crescents was graded into five categories: grade 0, lesion < 10%; grade 1, 10% ≤ lesion < 25%; grade 2, 25% ≤ lesion < 50%; grade 3, 50% ≤ lesion < 75%; and grade 4, lesion ≥ 75%. The extent of tubular atrophy and interstitial fibrosis was graded into four categories: grade 0, lesion < 5%; grade 1, 5% ≤ lesion < 20%; grade 2, 20% ≤ lesion < 50%; and grade 3, lesion ≥ 50%. The percentage of normal glomeruli was calculated as total glomeruli—global or segmental sclerotic lesions—crescents. The arteriosclerosis and arteriolosclerosis score was categorized as follows: none or low, 0; middle, 1; high, 2; and very high, 3. All specimens were obtained using
percutaneous needle biopsy. Specimens were fixed with 10% phosphate-buffered formalin (pH 7.2), embedded in paraffin, and cut into 4-μm-thick sections. The sections were stained with hematoxylin and eosin, periodic acid-Schiff, silver methenamine, and Masson trichrome for LM. Note that the average number of glomeruli collected in renal biopsies was 20 (3–38) for LN, 20 (6–53) for IgA-N, 23 (11–44) for IgA-VN, and 24 (8–63) for MPA. The percentage of crescent formation in each of the four glomerulonephritides was defined as C1 for less than 25%, C2 for greater than 25% and less than 50%, and C3 for greater than 50% (strict CreGN definition). Among 40 (%) LNs, 25 (62.5) had C1, 11 (27.5) had C2, and 4 (10.0) had C3. Of the 78 IgA-N cases, 58 (74.4) had C1, 17 (21.8) had C2, and 3 (3.8) had C3. Of the 31 IgA-VN cases, 27 (87.0) had C1, 2 (6.5) had C2, and 2 (6.5) had C3. Of the 44 MPA cases, 17 (38.6) had C1, 16 (36.4) had C2, and 11 (25.0) had C3. Three MPA cases had missing data, so the percentage of crescent formation was unknown.

2.4. Statistical Analyses. The two groups (type II and type III) and the four types of glomerulonephritis with crescents (MPA, IgA-N, IgA-VN, and LN) were compared. Each item was graded, and the factors contributing to renal prognosis (end-stage renal failure requiring renal replacement therapy) were analyzed using the Cox proportional hazards model. Subsequently, multivariate analysis was performed using factors that differed significantly in univariate analysis (p < 0.01). Data are expressed as mean ± standard deviation for normally distributed data and median ± interquartile range for non-normally distributed data and were analyzed using JMP® 14 software (SAS Institute Inc., Cary, NC, USA). The unpaired Student’s t-test and Mann–Whitney U test were used to compare the clinical findings for normally and non-normally distributed data, respectively, whereas the chi-squared test was used to compare the clinical and histological grades and sex distributions at the time of renal biopsy.

The cumulative renal survival rate until the endpoint was calculated according to the Kaplan–Meier method and log–rank test. Statistical significance was set at p < 0.05.

3. Results

Almost all clinical findings in the 196 cases of IgA-N, IgA-VN, LN, and MPA differed significantly, except for MAP, BMI, and U-RBC. For IgA-N, the degree of U-RBC did not differ significantly, but the urinary protein excretion was lower and Alb level was preserved compared to the same values in the other three types of disease. LN was also more common in women, whereas IgA-VN was more common in men. Compared to the other three types of disease, MPA patients were older and had significantly more deteriorated renal function at biopsy. Approximately 80% of patients with IgA-N and IgA-VN were administered antplatelet drugs, and 60% of patients with IgA-N were treated with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors. Moreover, although some complications occurred, there was a significant difference only in those with diabetes mellitus. Furthermore, MPA had a significantly higher ratio of crescent formation, global sclerosis, and interstitial fibrosis (Table 1).

In a comparison of characteristics at renal biopsy between the two groups, type III patients were found to be significantly older than type II patients, have a lower proportion of men, and have renal impairment. Type II patients had significantly lower levels of complement factors and a significantly higher incidence of hypertension; moreover, several patients were treated with antiplatelet drugs. Renal pathological findings showed that type III patients exhibited a significantly higher ratio of crescent formation, glomerular sclerosis, and tubulointerstitial fibrosis (Table 2).

One-year renal survival rates for patients with type III glomerulonephritis with crescents were significantly worse than those for patients with type II glomerulonephritis and crescentic lesions (p = 0.0002) (Figure 1). Univariate analysis revealed significant differences between the two groups in terms of disease, age, MAP, eGFR, total cholesterol, global sclerosis ratio, tubular atrophy, interstitial fibrosis, and the ratio of normal glomeruli. The proportion of crescents tended to be higher in type III patients but did not differ significantly. In multivariate analysis with renal prognosis as the outcome, only renal function, total cholesterol level, and global sclerotic lesions differed significantly (Table 3).

Only IgA-N and MPA showed a significant difference when renal prognosis was compared between the four disease types (p = 0.004) (Figure 2). Univariate analysis of IgA-N and MPA revealed significant differences in underlying disease, age, MAP, eGFR, total cholesterol, global sclerosis ratio, tubular atrophy, interstitial fibrosis, and the ratio of normal glomeruli. Underlying disease, renal function, global sclerotic lesion percentage, tubular atrophy and interstitial lesions, and percentage of normal glomeruli remained factors in the multivariate analysis with renal prognosis as the outcome, and only eGFR and global sclerotic lesions were significant factors (Table 4).

4. Discussion

The injury mechanism causing glomerular loop rupture remains the same regardless of the underlying disease triggering crescent formation. The presence or absence of crescent formation is thought to affect renal prognosis, which has led to the recent recognition of crescent formation as an independent renal function exacerbation factor for each glomerular disease [6, 9].

Recent reports of CreGN cases fulfilling the strict definition suggest that type I CreGN has a significantly worse renal prognosis compared with type II and type III CreGN [3, 4]. This may be due to differences in the underlying disease that triggers crescent formation; however, to our knowledge, no reports have outlined the detailed mechanisms to date.

In this study, only 12 and 14 cases of type II glomerulonephritis with crescents and type III glomerulonephritis with crescents, respectively, fulfilled the strict definition of CreGN, whereas type II glomerulonephritis with crescents did not include postinfectious glomerulonephritis or RPGN-
Table 1: Clinical and pathological findings according to the four classifications of rapid progressive glomerulonephritis.

| Clinical finding | LN (40) | Type II (n = 149) | Type III (n = 47) | p value |
|------------------|---------|------------------|------------------|---------|
| Age (years)      | 39.5 (32.3–50) | 33.5 (26–42.3) | 30.5 (24.5–44) | 64 (54–70.5) | <0.0001 |
| Sex (male/female)| 7/33 (M:18%) | 37/41 (M:47%) | 22/9 (M:71%) | 18/30 (M:38%) | 0.0002 |
| Mean arterial pressure (mmHg) | 91 (84.3–107.2) | 92.2 (84.9–100) | 93 (81.7–98.7) | 96 (82.7–105.8) | 0.6150 |
| Body mass index | 22.0 (20.5–23.6) | 21.3 (19.7–23.4) | 21.4 (19.3–24.4) | 21.6 (19.9–24.3) | 0.5850 |
| Total serum protein (g/dL) | 5.8 (4.7–6.2) | 6.6 (6.1–7) | 6.5 (5.9–6.9) | 6.6 (6.2–7.2) | <0.0001 |
| Serum albumin (g/dL) | 2.9 (2.2–3.5) | 3.9 (3.5–4.2) | 3.7 (3.2–4.2) | 3.2 (3.6–4) | <0.0001 |
| Blood urea nitrogen (mg/dL) | 18 (13.4–23.9) | 14 (12.1–17.8) | 13.1 (11.9–17.2) | 26.7 (18.2–43.2) | <0.0001 |
| Serum creatinine (mg/dL) | 0.79 (0.62–1.09) | 0.78 (0.67–1.04) | 0.78 (0.67–0.91) | 1.71 (1.03–2.76) | <0.0001 |
| Estimated GFR (mL/min/1.73 m²) | 71.4 (46.3–93.1) | 75.9 (57–95.6) | 85.5 (69.5–107.8) | 25 (16.8–42.9) | <0.0001 |
| Urine protein (g/g creatinine) | 1.9 (0.88–4.7) | 1.19 (0.66–2.34) | 2 (0.78–3.37) | 1.54 (0.74–2.75) | 0.0340 |
| Urine red blood cell count (counts/HPF) | 20 (5–30) | 20 (10–42.5) | 30 (10–50) | 20 (10–30) | 0.2950 |
| IgG (mg/dL) | 1183 (849–1685) | 1049 (850–1298) | 893.5 (737–1110) | 1338 (1047–1626) | 0.0002 |
| IgA (mg/dL) | 232 (170.5–305) | 283 (221–386) | 251 (196.3–369.5) | 215 (166–281) | 0.0027 |
| IgM (mg/dL) | 73.5 (48–101) | 94.6 (85–121) | 90.3 (85–116) | 106.6 (95.8–121) | <0.0001 |
| C3 (mg/dL) | 27/9 (10–42.5) | 25 (10–20) | 24 (10–30) | 19 (10–41) | 0.2208 |
| C4 (mg/dL) | 20 (7.7–36.7) | 16.7 (10.2–26.5) | 14.3 (9.1–18.2) | 28 (20.6–51.7) | <0.0001 |
| Complications (%) | 1: Diabetes mellitus | 3 (7.5) | 2 (2.6) | 4 (12.9) | 5 (10.4) | 0.0786 |
| Treatment (%) | 2: Hypertension | 10 (25) | 22 (28.2) | 8 (25.8) | 20 (41.7) | 0.0698 |
| Pathological finding | 3: Dyslipidemia | 11 (27.5) | 20 (25.6) | 8 (25.8) | 24 (50) | 0.8289 |
| Percentage of normal glomeruli (%) | 5 (12.5) | 9 (11.5) | 1 (3.2) | 9 (18.8) | 0.2362 |
| Arteriolar sclerosisb (0/1/2/3) | 25/7/4/2 | 20 (5–30) | 24 (7.7) | 16 (33.3) | <0.0001 |
| Antipatelet drug | 21 (52.5) | 62 (79.5) | 24 (50) | 25 (52.1) | 0.0282 |
| ACEI/ARB | 13 (32.5) | 47 (60.3) | 14 (45.2) | 25 (52.1) | 0.0282 |

GFR, Glomerular filtration rate; HPF, high-power field; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. Tubular atrophy and interstitial fibrosis score: <5%, 0; 5 ≤ lesion < 20, 1; 20 ≤ lesion < 50, 2; ≥50, 3. Arteriosclerosis and arteriolar sclerosis score: none or low, 0; middle, 1; high, 2; and very high 3.

Type IgA-N. Therefore, unlike the previous report on CreGN, this was considered a unique finding in cases of glomerulonephritis with crescents [2–4]. However, even in the present study, type III glomerulonephritis with crescents had a significantly poorer renal prognosis compared to type II glomerulonephritis with crescents. Our findings strongly suggest that the difference between the underlying type II and type III glomerulonephritis that triggers crescent formation may significantly affect renal prognosis.

Surprisingly, multivariate analysis did not identify the type of underlying disease as an exacerbating factor for renal prognosis when type II glomerulonephritis and type III glomerulonephritis with crescents were compared. In all multivariate analyses, eGFR calculated using creatinine levels at the time of renal biopsy and global sclerosis on renal biopsy were extracted as factors exacerbating renal prognosis. However, it is worth noting that this study did not identify any factors that are clinically suggested to exacerbate renal prognosis, including age, blood pressure, or proteinuria [10, 11]. Histologically, it was also contrary to our expectation that the crescent ratio, tubular atrophy, interstitial fibrosis, and atherosclerotic lesions were not identified as renal prognosis exacerbation factors [12]. These results suggest that the presence or absence of global sclerosis is strongly correlated with renal prognosis in cases of glomerulonephritis with crescents. In our study, IgA-N was the most common case. For IgA-N, the Oxford classification (MEST) was proposed in 2009 as a criterion to accurately predict renal prognosis from pathological diagnosis [13]. Subsequently, the importance of crescents formation (especially crescents >25% of glomeruli, i.e., C2) was recognized and the MEST-C score was proposed [14]. For IgA-VN, a pediatric case was reported in which renal prognosis was examined using MEST-C scoring, and S1 and T1 and T2 were significantly associated with renal prognosis, while C2 lesions were associated with decreased renal function at the time of renal biopsy [15]. In our study, the degree of crescent formation was not significantly associated with renal
prognosis on multivariate analysis. This may be due to the fact that we did not include cases without crescent formation, that is, C0 on the MEST-C score, and that all cases were treated with immunosuppressive drugs, including methylprednisolone pulse therapy [16]. Of the present cases, 15 of 40 LN (37.5%), 20 of 78 IgA-N (25.6%), 4 of 31 IgA-VNs (12.9%), and 27 of 44 MPA (51.4%) had crescents formation >25%. Three cases of MPA could not be evaluated due to missing data.

Several reports have been written on the relationship between global sclerosis and the ratio of crescent formation in ANCA-associated vasculitis-associated glomerulonephritis. The sclerotic type of vasculitis-associated glomerulonephritis consisting of primarily global sclerosis reportedly had a worse renal prognosis than the crescentic type with a large crescentic ratio, similar to the results of the present study [17, 18]. The percentage of normal glomeruli as well as global glomerulosclerosis was also considered important in previous reports [17, 19]; however, multivariate analysis of the percentage of normal glomeruli in patients with MPA only revealed that total nodal sclerosis was a significant factor associated with renal prognosis (Supplementary Table 1). The reason that the ratio of crescent formation does not directly correlate with renal prognosis can be understood as a reflection of the difference in response to the treatment of cellular crescent and global sclerosis.

However, the final stage of the crescent glomerular injury process is a compression of the glomerulus from the outside, resulting in glomerular collapse, which rapidly induces global sclerosis, similar to a collapsing variant in focal global sclerosis [20, 21]. In previous reports of CreGN, type I and type III CreGN were aggressive to the extent that even patients with little or no crescent formation were suggested to be considered for substantial immunosuppressive treatment [22]. Therefore, clinicians should provide aggressive immunosuppressive treatment as soon as possible in cases of glomerulonephritis when a renal biopsy reveals even one crescent lesion.

Our study had several limitations. First, the observation period for studying renal prognosis was very short. There were no cases of type I CreGN, ANCA-associated vasculitis is extremely similar to MPA in Japan, unlike in Europe and

---

**Table 2: Clinical and pathological findings in type II and type III rapid progressive glomerulonephritis at the time of renal biopsy.**

| Clinical findings | Type II (n = 149) | Type III (n = 47) | p value |
|-------------------|------------------|------------------|---------|
| **Clinical findings** |                  |                  |         |
| Age (years)       | 34 (26–45)       | 64 (54–70.5)     | <0.0001 |
| Sex (male/female) | 66/83 (M: 44%)   | 18/30 (M: 38%)   | <0.0001 |
| Mean arterial pressure (mmHg) | 92.3 (84.7–100) | 96 (82.7–105.8) | 0.2065  |
| Body mass index   | 21.5 (19.8–23.5) | 21.6 (19.9–24.3) | 0.6903  |
| Total serum protein (g/dL) | 6.3 (5.7–6.9)   | 6.6 (6.2–7.2)    | 0.0238  |
| Serum albumin (g/dL) | 3.7 (3.1–4.1)   | 3.2 (2.6–4)      | 0.0438  |
| Blood urea nitrogen (mg/dL) | 14.5 (12.1–19.4) | 26.7 (18.2–43.2) | <0.0001 |
| Serum creatinine (mg/dL) | 0.79 (0.67–1.02) | 1.71 (1.03–2.76) | <0.0001 |
| Estimated GFR (mL/min/1.73 m²) | 75.8 (59.1–98.0) | 25 (16.8–42.9) | <0.0001 |
| Urine protein (g/g creatinine) | 1.33 (0.71–2.73) | 1.54 (0.74–2.75) | 0.7207  |
| Urine red blood cell count (counts/HPF) | 20 (10–50) | 20 (10–30) |
| IgG (mg/dL)       | 1037 (807–1323)  | 1338 (1047–1626) | 0.0006  |
| IgA (mg/dL)       | 267 (198–366)    | 215 (166–281)    | 0.0037  |
| IgM (mg/dL)       | 106 (79–149)     | 89 (58–115)      | 0.0269  |
| CH50 (mg/dL)      | 39.5 (32.1–47.8) | 51.3 (43.6–59.0) | <0.0001 |
| C3 (mg/dL)        | 91.5 (72.9–109.5)| 106.6 (95.8–121) | <0.0001 |
| C4 (mg/dL)        | 21.5 (15.3–26.9) | 26.9 (22.0–34.1) | <0.0001 |
| **Complications (%)** |                  |                  |         |
| Diabetes mellitus | 9 (6)            | 5 (10.4)         | 0.2912  |
| Hypertension      | 40 (26.8)        | 20 (41.7)        | 0.0086  |
| Dyslipidemia      | 39 (26.2)        | 24 (50)          | 0.5206  |
| Hyperuricemia     | 15 (10.1)        | 9 (18.8)         | 0.0422  |
| **Treatment (%)** |                  |                  |         |
| Antiplatelet drug | 107 (72)         | 16 (33.3)        | 0.0002  |
| ACEI/ARB          | 74 (50)          | 25 (52.1)        | 0.3300  |
| **Pathological findings** |                  |                  |         |
| Percentage of global glomerulosclerosis (%) | 10.0 (0–22.2) | 27.8 (6.7–38.4) | <0.0001 |
| Percentage of crescents (Cellular/fibrocellular/fibrous) (%) | 15.9 (9.1–27.3) | 28 (20.6–51.7) | <0.0001 |
| Tubulointerstitial lesions* (0/1/2/3) | 34/7732/5 | 9/11/11/12 | 0.0001 |
| Arteriosclerosisb (0/1/2/3) | 85/2924/5 | 16/13/11/4 | 0.0094 |
| Arteriolar sclerosisb (0/1/2/3) | 78/43/24/3 | 16/19/8/1 | 0.1548 |
| **Percentage of normal glomeruli (%)** | 67.0 (49.0–80.5) | 34.5 (21.0–54.5) | <0.0001 |

GFR, glomerular filtration rate; HPF, high-power field; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. aTubular atrophy and interstitial fibrosis score: ≤5%, 0; ≤20% < 50, 1; 20% < 50, 2; ≥ 50, 3. bArteriosclerosis and arteriolosclerosis score: none or low, 0; middle, 1; high, 2; and very high, 3.
**Figure 1:** One-year renal survival in patients with type II and type III glomerulonephritis and crescents. Analysis of the 1-year survival rate using the Kaplan–Meier method shows that the renal prognosis of patients with type III glomerulonephritis and crescents was significantly worse ($p = 0.0002$). The solid line indicates the type II glomerulonephritis with the crescent group, whereas the dotted line indicates the type III glomerulonephritis with the crescent group.

**Table 3:** Univariate and multivariate analysis of factors affecting renal prognosis between type II and type III rapid progressive glomerulonephritis.

|                         | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | HR  | 95% CI  | $p$ value | HR  | 95% CI  | $p$ value |
| Type III (vs. type II)  | 15.08 | 3.08–73.9 | 0.0001 | 0.07 | 0.01–2.52 | 0.10522 |
| Age (15 years of increase) | 2.60 | 1.45–4.67 | 0.0005 | 0.67 | 0.15–2.99 | 0.59377 |
| Male (vs. Female)       | 0.92 | 0.25–3.38 | 0.9036 |       |       |           |
| MAP (10 mm Hg increase) | 2.05 | 1.15–3.67 | 0.0125 |       |       |           |
| BMI (3 kg/m2 increase)  | 1.23 | 0.70–2.16 | 0.463  |       |       |           |
| eGFR (30 mL/min/1.73 m2 decrease) | 17.57 | 2.55–121 | <0.0001 | 8.57E+08 | – | 0.00012 |
| T-chol (30 mg/dL increase) | 0.46 | 0.26–0.81 | 0.0034 | 0.29 | 0.10–0.86 | 0.00448 |
| TG (30 mg/dL increase)  | 0.35 | 0.07–1.82 | 0.0541 |       |       |           |
| U-Pro (0.5 g Cr increase) | 1.13 | 0.88–1.45 | 0.3329 |       |       |           |
| U-RBC (25 counts/HPF increase) | 0.98 | 0.54–1.76 | 0.9348 |       |       |           |
| ACEI/ARB use (vs. nonuse) | 0.89 | 0.22–3.65 | 0.8677 |       |       |           |
| Antiplatelet drugs use (vs. nonuse) | 0.75 | 0.16–3.46 | 0.7168 |       |       |           |
| Percentage of global glomerulosclerosis$^a$ | 1.11 | 1.06–1.16 | <0.0001 | 8.99 | 1.40–57.9 | 0.00176 |
| Percentage of crescents$^b$ (cellular/fibrocellular/fibrous) | 1.83 | 1.01–3.33 | 0.0486 |       |       |           |
| Tubular atrophy and interstitial fibrosis$^c$ | 6.69 | 2.22–22.2 | 0.0001 | 0.83 | 0.19–3.55 | 0.80201 |
| Percentage of normal glomeruli$^d$ | 0.22 | 0.08–0.58 | 0.0004 | 1.84 | 0.28–12.2 | 0.51339 |
| Arteriosclerosis score$^e$ | 1.83 | 1.83–0.95 | 0.071  |       |       |           |
| Arteriolsclerosis score$^f$ | 2.67 | 1.26–6.03 | 0.0111 |       |       |           |

*HR, hazard ratio; CI, confidence interval; MAP, mean arterial pressure; BMI, body mass index; Alb, serum albumin; eGFR, estimated glomerular filtration rate; T-chol, total cholesterol; TG, triglycerides; U-Pro, total urine protein; U-RBC, urine red blood cell count; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. $^a$Global glomerulosclerosis score: < 10%, 0; 10 ≤ lesion < 25%, 1; 25 ≤ lesion < 50%, 2; 50 ≤ lesion < 75%, 3; ≥75%, 4. $^b$Crescent score: <10%, 0; 10 ≤ lesion < 25%, 1; 25 ≤ lesion < 50%, 2; 50 ≤ lesion < 75%, 3; ≥75%, 4. $^c$Tubular atrophy and interstitial fibrosis score: <5%, 0; 5 ≤ lesion < 20, 1; 20 ≤ lesion < 50, 2; ≥50, 3. $^d$Normal glomeruli score: > 75%, 0; 50 < lesion ≤ 75, 1; 25 < lesion ≤ 50, 2; ≤ 25, 3. $^e$Arteriosclerosis and arteriolsclerosis score: none or low, 0; middle, 1; high, 2; and very high, 3.
the United States, and the treatment regimen is mild (Supplementary Table 2). Despite these limitations, the renal function (eGFR) at the time of renal biopsy and global glomerulosclerosis were significant predictors of renal prognosis in crescentic glomerulonephritis in our analysis, as in previous studies [3, 18, 19].

**Figure 2**: One-year renal survival according to the four classifications of glomerulonephritis with crescents. One-year renal survival was analyzed using the Kaplan–Meier method, and a significant difference was only observed between MPA and IgA-N ($p = 0.004$). The solid line indicates IgA-N. The dotted lines indicate type III MPA. MPA, microscopic polyangiitis; IgA-N, immunoglobulin A nephropathy; LN, lupus nephritis; IgA-VN, IgA vasculitis with nephritis.

**Table 4**: Univariate and multivariate analysis of factors affecting renal prognosis microscopic polyangiitis and immunoglobulin A nephropathy.

| Factor                              | Univariate analysis | Multivariate analysis |
|-------------------------------------|---------------------|-----------------------|
|                                     | HR  | 95% CI        | $p$ value | HR  | 95% CI        | $p$ value |
| MPA (vs. IgA-N)                     | 15.8| 1.91–131      | 0.0009    | 0.35| 0.01–37.9     | 0.65774   |
| Age (15 years increase)             | 2.01| 1.13–3.60     | 0.0129    |     |               |           |
| Male (vs. Female)                   | 0.64| 0.15–2.67     | 0.5302    |     |               |           |
| MAP (10 mm Hg increase)             | 2.06| 1.08–3.93     | 0.0225    |     |               |           |
| BMI (3 kg/m2 increase)              | 1.10| 0.61–1.99     | 0.7415    |     |               |           |
| eGFR (30 mL/min/1.73 m2 decrease)   | 13.0| 1.88–90.5     | <0.0001   | 4.6E+0.7| –             | 0.04942   |
| T-chol (30 mg/dL increase)          | 0.50| 0.28–0.92     | 0.0170    |     |               |           |
| TG (30 g/dL increase)               | 0.50| 0.11–2.33     | 0.2424    |     |               |           |
| U-Prot (0.5 g/g Cr increase)        | 1.30| 0.98–1.73     | 0.0907    |     |               |           |
| U-RBC (25 counts/HPF increase)      | 0.89| 0.47–1.70     | 0.7247    |     |               |           |
| ACEI/ARB use (vs. nonuse)           | 0.88| 0.19–4.13     | 0.8741    |     |               |           |
| Antplatelet drugs use (vs. nonuse)  | 1.05| 0.18–6.01     | 0.9526    |     |               |           |
| Percentage of global glomerulosclerosis$^a$ | 74.3 | 6.89–803 | <0.0001 | 23.3 | 1.41–386 | 0.00127 |
| Percentage of crescents$^b$ (cellular/fibrocellular/fibrous) | 1.96 | 0.98–3.89 | 0.0564 |     |               |           |
| Tubular atrophy and interstitial fibrosis$^c$ | 10.0 | 2.42–41.7 | 0.0001 | 2.51 | 0.50–12.6 | 0.23657 |
| Percentage of normal glomeruli$^d$  | 0.08| 0.02–0.38     | <0.0001   | 0.38| 0.02–7.74     | 0.53297   |
| Arteriosclerosis score$^e$          | 1.89| 0.90–4.10     | 0.0903    |     |               |           |
| Arteriolosclerosis score$^e$        | 2.60| 1.13–6.57     | 0.0252    |     |               |           |

*HR, hazard ratio; CI, confidence interval; MAP, mean arterial pressure; BMI, body mass index; Alb, serum albumin; eGFR, estimated glomerular filtration rate; T-chol, total cholesterol; TG, triglycerides; U-Prot, total urine protein; U-RBC, urine red blood cell count; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. $^a$Global glomerulosclerosis score: <10%, 0; 10% ≤ lesion < 25%, 1; 25% ≤ lesion < 50%, 2; 50% ≤ lesion < 75%, 3; ≥75%, 4. $^b$Crescent score: <10%, 0; 10% ≤ lesion < 25%, 1; 25% ≤ lesion < 50%, 2; 50% ≤ lesion < 75%, 3; ≥75%, 4. $^c$Tubular atrophy and interstitial fibrosis score: <5%, 0; ≤ lesion < 20, 1; 20% ≤ lesion < 50, 2; ≥50, 3. $^d$Normal glomeruli score: >75%, 0; 50% ≤ lesion ≤ 75, 1; 25% ≤ lesion ≤ 50, 2; ≤ 25, 3. $^e$Arteriosclerosis and arteriolosclerosis score: none or low, 0; middle, 1; high, 2; and very high 3.
5. Conclusions

In cases of glomerulonephritis with at least one crescentic lesion, global sclerosis and eGFR calculated using the creatinine value at renal biopsy were independent factors for exacerbated renal prognosis, regardless of the underlying disease.

Abbreviations

IGA: Immunoglobulin A
RPGN: Rapid progressive glomerulonephritis
CreGN: Crescentic glomerulonephritis
GBM: Glomerular basement membrane
IgA-N: Immunoglobulin A nephropathy
ANCA: Anti-neutrophil cytoplasmic autoantibody
MPA: Microscopic polyangiitis
Alb: Serum albumin
BMI: Body mass index
MAP: Mean arterial pressure;
eGFR: estimated glomerular filtration rate
U-RBC: Urinary red blood cell count.

Data Availability

All data concerning each case are presented in the manuscript.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors’ Contributions

KK was the corresponding author responsible for writing this article. TT, KA, YM, and TM treated the patients and wrote the manuscript. KU and KN participated in patient care. All authors read and approved the final manuscript. TN and KA contributed equally to this study.

Acknowledgments

The authors would like to thank Editage (https://www.editage.com) for English language editing.

Supplementary Materials

Supplementary Table 1: Univariate and multivariate analysis of factors affecting renal prognosis microscopic polyangiitis.
Supplementary Table 2: Clinical score, clinical grade, and treatment regimen for microscopic polyangiitis therapy in Japan. (Supplementary Materials)

References

[1] K. Kitagawa, K. Furuichi, Y. Shinozaki et al., “Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis,” Clinical and Experimental Nephrology, vol. 17, no. 6, pp. 858–865, 2013.

[2] W. Lin, M. Chen, Z. Cui, and M. H. Zhao, “The immunopathological spectrum of crescentic glomerulonephritis: a survey of 106 patients in a single Chinese center,” Nephron Clinical Practice, vol. 116, no. 1, pp. c65–c73, 2010.

[3] N. Oudah, Z. Al Duhailib, K. Alsaa et al., “Glomerulonephritis with crescents among adult saudi patients outcome and its predictors,” Clinical and Experimental Medicine, vol. 12, no. 2, pp. 121–125, 2012.

[4] S. Chen, Z. Tang, H. Xiang et al., “Etiology and outcome of crescentic glomerulonephritis from a single center in China: a10-year review,” American Journal of Kidney Diseases, vol. 67, no. 3, pp. 376–383, 2016.

[5] A. Koyama, K. Yamagata, H. Makino et al., “A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity,” Clinical and Experimental Nephrology, vol. 13, no. 6, pp. 633–650, 2009.

[6] G. Moroni and C. Ponticelli, “Rapidly progressive crescentic glomerulonephritis: early treatment is a must,” Autoimmunity Reviews, vol. 13, no. 7, pp. 723–729, 2014.

[7] X. Shao, B. Li, L. Cao et al., “Evaluation of crescent formation as a predictive marker in immunoglobulin A nephropathy: a systematic review and meta-analysis,” Oncotarget, vol. 8, no. 28, pp. 46436–46448, 2017.

[8] I. M. Bajema, S. Wilhelmus, C. E. Alpers et al., “Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices,” Kidney International, vol. 93, no. 4, pp. 789–796, 2018.

[9] C. Hénique, C. Papista, L. Guyonnet, O. Lenoir, and P. L. Tharaux, “Update on crescentic glomerulonephritis,” Seminars in Immunopathology, vol. 36, no. 4, pp. 479–490, 2014.

[10] R. Hanratty, M. Chonchol, E. P. Havranek et al., “Relationship between blood pressure and incident chronic kidney disease in hypertensive patients,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 11, pp. 2605–2611, 2011.

[11] M. Tonelli, S. W. Klarenbach, A. M. Lloyd et al., “Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria,” Kidney International, vol. 80, no. 12, pp. 1306–1314, 2011.

[12] S. Sethi and F. C. Fervenza, “Standardized classification and reporting of glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 34, no. 2, pp. 193–199, 2019.

[13] Working Group of the International IG A Nephropathy Network and the Renal Pathology Society, I. S. D. Roberts, H. T. Cook et al., “The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility,” Kidney International, vol. 76, no. 5, pp. 546–556, 2009.

[14] H. Trimarchi, J. Barratt, D. C. Cattran et al., “Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group,” Kidney International, vol. 91, no. 5, pp. 1014–1021, 2017.

[15] K. Xu, L. Zhang, J. Ding et al., “Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis,” Journal of Nephrology, vol. 31, no. 2, pp. 279–286, 2018.

[16] M. Haas, J. C. Verhave, Z. H. Liu et al., “A multicenter study of the predictive value of crescents in IgA nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 2, pp. 691–701, 2017.
[17] M. Hilhorst, B. Wilde, P. van Breda Vriesman, P. van Paassen, J. W. Cohen Tervaert, and L. R. Registry, “Estimating renal survival using the ANCA-associated GN classification,” Journal of the American Society of Nephrology, vol. 24, no. 9, pp. 1371–1375, 2013.

[18] F. Diaz-Crespo, J. Villacorta, M. Acevedo et al., “The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study,” Human Pathology, vol. 52, pp. 119–127, 2016.

[19] S. R. Brix, M. Noriega, P. Tennstedt et al., “Development and validation of a renal risk score in ANCA-associated glomerulonephritis,” Kidney International, vol. 94, no. 6, pp. 1177–1188, 2018.

[20] E. Fujita, K. Nagahama, A. Shimizu et al., “Glomerular capillary and endothelial cell injury is associated with the formation of necrotizing and crescentic lesions in crescentic glomerulonephritis,” Journal of Nippon Medical School, vol. 82, no. 1, pp. 27–35, 2015.

[21] V. D’Agati, J. M. Alster, J. C. Jennette et al., “Association of histologic variants in FSGS clinical trial with presenting features and outcomes,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 3, pp. 399–406, 2013.

[22] J. Charles Jennette, “Rapidly progressive crescentic glomerulonephritis,” Kidney International, vol. 63, no. 3, pp. 1164–1177, 2003.